The Healthcare Data

Nexus Pharmaceuticals Introduces Tranexamic Acid

Nexus Pharmaceuticals Introduces Tranexamic Acid

Nexus Pharmaceuticals Expands Portfolio with the Launch of Tranexamic Acid Nexus Pharmaceuticals, LLC has announced the official launch of Tranexamic Acid, marking a significant milestone in the company’s ongoing commitment to providing life-saving medications. This addition to Nexus’ growing pharmaceutical…

CEL-SCI Prices $2.5M Offering

CEL-SCI Prices $2.5M Offering

CEL-SCI Prices $2.5M Offering to Advance Cancer Immunotherapy Development CEL-SCI Corporation (NYSE American: CVM), a biotechnology company focused on cancer immunotherapy, has announced the pricing of a best-efforts public offering to raise approximately $2.56 million. The offering comprises 16,000,000 shares…